Cambrex

About Cambrex

Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance development and manufacturing across the entire drug lifecycle, as well as comprehensive analytical and IND enabling services.

With over 40 years of experience and a team of 2,000 experts servicing global clients from North America and Europe, Cambrex offers a range of specialized drug substance technologies and capabilities, including continuous flow, controlled substances, solid-state science, material characterization, and highly potent APIs.

Sales Markets

Africa
Central America (e.g. Mexico)
East Asia (e.g. China, Japan, Korea)
Europe - EU countries
Europe - non EU (e.g. UK, Russia, ex-CIS countries)
Middle East Region (e.g. UAE)
North America (USA, Canada)
Oceania
South America (e.g. Brazil, Colombia)
South Asia (e.g. India, Pakistan, Sri Lanka)
South East Asia (e.g. Thailand, Philippines, Singapore)

CPHI North America 2024

Pennsylvania Convention Center, Philadelphia

07 May 2024 - 09 May 2024

View Exhibitor Profile

CPHI Milan 2024

Fiera Milano, Italy

08 Oct 2024 - 10 Oct 2024

View Exhibitor Profile

Cambrex Resources (6)

News CPHI Pharma Awards 2023 – API Development and Innovation Winners: Snapdragon Chemistry, a Cambrex Company

After another year of impressive nominations for the CPHI Pharma Awards our winners were announced at CPHI Barcelona in October. In this series of interviews, we speak to the teams behind the award-winning projects, concepts, and technologies.

16 Jan 2024
Video Our Corporate Video

Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance, drug product, and analytical services across the entire drug lifecycle. With over 40 years of experience and a growing team of over 2,400 experts servicing global clients from North America and Europe, Cambrex is a trusted partner in branded and generic markets for API and finished dosage form development and manufacturing.

2023-04-06
Sponsored Content Cambrex Celebrates Grand Opening of New Q1 Scientific Facility in Belgium and Secures First Stability Storage Commercial Agreement

East Rutherford, NJ – May 31, 2023 – Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, yesterday celebrated the grand opening of its new Q1 Scientific facility in Belgium and announced the signing of a new commercial agreement with QUALIblood, a Belgium-based contract research organization supporting pharmaceutical companies, invitro diagnosis companies, hospitals and universities with analytical services for blood investigations and hemocompatibility testing.

1 Jun 2023
Brochure Drug substance capabilities and expertise overview

Active ingredients, Dynamic people - From laboratory scale to commercial supply, enjoy working with the experts at Cambrex on your API.
Brochure Drug product capabilities and expertise overview

Drug formulations, Expertly finished - From pre-formulation registration batches and clinical supply to commercial manufacturing and packaging, Cambrex delivers your complex dosage forms with expertise.
Brochure Analytical capabilities and expertise overview

Analytical solutions, Quality assured - Trust our analytical development and testing experts to rapidly advance your molecule for the greatest chance of success.

CPHI Online is the largest global marketplace in the pharma ingredients industry